Trials / Completed
CompletedNCT04875962
A Study to Test the Safety, Tolerability, and Pharmacokinetics of UCB0599 in Healthy Study Participants and Patients With Parkinson's Disease (PD)
A Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of UCB0599 in Healthy Study Participants and Patients With Parkinson's Disease (PD)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 31 (actual)
- Sponsor
- UCB Biopharma S.P.R.L. · Industry
- Sex
- All
- Age
- 40 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
The purpose of the study is to evaluate the safety and tolerability after administration of multiple doses and the pharmacokinetics (PK) of single and multiple doses of UCB0599 in healthy study participants and participants with Parkinson's Disease (PD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | UCB0599 | Participants will receive an assigned dosage regimen of UCB0599 during the Treatment Period. |
| DRUG | Placebo | Participants will receive an assigned dosage regimen of Placebo during the Treatment Period to maintain the blinding. |
Timeline
- Start date
- 2019-05-06
- Primary completion
- 2020-02-19
- Completion
- 2020-02-19
- First posted
- 2021-05-06
- Last updated
- 2021-05-06
Locations
6 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04875962. Inclusion in this directory is not an endorsement.